Results 21 to 30 of about 5,595 (162)
Hepatitis C Virus Infection: Looking for Interferon Free Regimens
Recent developments of new drugs′ combinations are changing the treatment paradigm in hepatitis C virus infection. Due to the side effect profile of pegylated interferons, interferon‐sparing regimens have become the main target in chronic hepatitis C treatment research.
J. González-Moreno +3 more
wiley +1 more source
Introducing Polyautoimmunity: Secondary Autoimmune Diseases No Longer Exist
Similar pathophysiological mechanisms within autoimmune diseases have stimulated searches for common genetic roots. Polyautoimmunity is defined as the presence of more than one autoimmune disease in a single patient. When three or more autoimmune diseases coexist, this condition is called multiple autoimmune syndrome (MAS).
Adriana Rojas-Villarraga +5 more
wiley +1 more source
Toll‐Like Receptors in Secondary Obstructive Cholangiopathy
Secondary obstructive cholangiopathy is characterized by intra‐ or extrahepatic bile tract obstruction. Liver inflammation and structural alterations develop due to progressive bile stagnation. Most frequent etiologies are biliary atresia in children, and hepatolithiasis, postcholecystectomy bile duct injury, and biliary primary cirrhosis in adults ...
A. G. Miranda-Díaz +6 more
wiley +1 more source
Treatment with tyrosine kinase inhibitors (TKIs) has drastically improved overall survival (OS) of patients with advanced GIST. The aim of this study is to evaluate the results of treatment with different TKIs on advanced GIST and identify prognostic factors for OS.
Ninna Aggerholm-Pedersen +7 more
wiley +1 more source
Caffeine′s Vascular Mechanisms of Action
Caffeine is the most widely consumed stimulating substance in the world. It is found in coffee, tea, soft drinks, chocolate, and many medications. Caffeine is a xanthine with various effects and mechanisms of action in vascular tissue. In endothelial cells, it increases intracellular calcium stimulating the production of nitric oxide through the ...
Darío Echeverri +5 more
wiley +1 more source
Interleukin‐12 (IL‐12) is an important cytokine for maintainence of normal systemic defense and bioregulation. The Japanese herbal medicine Sho‐saiko‐to (TJ‐9) has been administered to 1.5 million Japanese patients with chronic liver diseases. TJ‐9 is known to significantly suppress cancer development in the liver and has macrobiotic effects.
Masayoshi Yamashiki +5 more
wiley +1 more source
Liver cirrosis and complication risk management
Liver cirrhosis (LC) takes the main place in the structure of the pathology of the digestive system in terms of the frequency of mortality, as well as in the development of fatal and poorly controlled complications, which requires the search for effective methods for preventing the progression of the disease and the development of complications.
Igor G. Bakulin +3 more
openaire +4 more sources
Inmunología de la cirrosis hepática y sus tratamientos. [PDF]
La cirrosis hepática es una condición clínica caracterizada por la incapacidad del hígado de funcionar de manera correcta debido a un daño hepático ocasionado durante un largo periodo de tiempo.
Martínez Redondo, José Antonio
core +1 more source
Fecal extracellular vesicles (fEVs) from DILI patients have a distinct bacterial profile. This study provides evidence that bacterial EVs enter the bloodstream. DILI and MASLD F≥3 fEVs increase the pro‐inflammatory response and hepatocyte steatosis. FEVs from DILI patients enhance the hepatotoxic potential of diclofenac.
Antonio J. Ruiz‐Malagón +16 more
wiley +1 more source
The Economics of Liver Fibrosis Diagnosis: Systematic Review of Non‐Invasive Test Cost‐Effectiveness
ABSTRACT Hepatic diseases progress silently, leading to fibrosis, cirrhosis, and hepatocellular carcinoma. Although liver biopsy remains the gold standard for fibrosis assessment, it is limited by invasiveness and sampling variability. Non‐invasive liver tests (NILTs) can mitigate biopsy‐related risks.
Marilia Mastrocolla de Almeida Cardoso +7 more
wiley +1 more source

